

June 11, 2025



## **bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas' Leadership Board**

SAN ANTONIO--(BUSINESS WIRE)-- [bioAffinity Technologies, Inc.](#) (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other diseases of the lung, today announced that its President and CEO, Maria Zannes, has been selected to serve on the American Lung Association in Texas' Leadership Board, a distinguished group of healthcare professionals and advocates committed to advancing lung health.

As a member of the Texas Leadership Board, Ms. Zannes will play an important role in supporting the Lung Association's mission to improve lives by preventing lung disease and promoting lung health through research, education and advocacy. Board members contribute their expertise to raise the Lung Association's profile in the community, advocate for lung health and increase resources to fund local programs and services.

"We are pleased to welcome Maria to our Texas Leadership Board," said Charlotte Maffia, Executive Director of the American Lung Association in Texas. "Her business experience and commitment to lung health and better outcomes for lung cancer patients will be a tremendous asset to our state organization."

As bioAffinity Technologies CEO and President, Ms. Zannes has built a team of award-winning scientists and executives who are advancing noninvasive tests to detect lung cancer and other lung diseases such as asthma and chronic obstructive pulmonary disease (COPD), including [CyPath® Lung](#), a noninvasive, accurate test for lung cancer.

"It is an honor to be invited to join the American Lung Association in Texas' Leadership Board," Ms. Zannes said. "The Lung Association is a world leader in advancing prevention, diagnosis and treatment of lung disease, a mission that bioAffinity Technologies shares as we continue to grow CyPath® Lung and expand into precision diagnostics for COPD and asthma. The ALA is science based and mission driven, as are we. I look forward to working with the board to advance the association's work in Texas."

### **About the American Lung Association**

The American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and research. The work of the American Lung Association is focused on four strategic

imperatives: to defeat lung cancer; to champion clean air for all; to improve the quality of life for those with lung disease and their families; and to create a tobacco-free future. For more information about the American Lung Association, which has a 4-star rating from Charity Navigator and is a Platinum-Level GuideStar Member, call 1-800-LUNGUSA (1-800-586-4872) or visit: [Lung.org](https://www.lung.org).

### **About CyPath® Lung**

CyPath® Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath® Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. [Clinical study results](#) demonstrated that CyPath® Lung had 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Diagnosing and treating early-stage lung cancer can improve outcomes and increase patient survival. For more information, visit [www.cypathlung.com](https://www.cypathlung.com).

### **About bioAffinity Technologies, Inc.**

bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company's first product, [CyPath® Lung](#), is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by [Precision Pathology Laboratory Services](#), a subsidiary of bioAffinity Technologies. For more information, visit [www.bioaffinitytech.com](https://www.bioaffinitytech.com).

### **Forward-Looking Statements**

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding Ms. Zannes' expected contribution to the American Lung Association in Texas' Leadership Board, the Company continuing to grow CyPath® Lung, and its ability to expand into precision diagnostics for COPD and asthma. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company's ability to grow CyPath® Lung and expand into precision diagnostics for COPD and asthma as planned, and other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any

forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20250611409891/en/>

**bioAffinity Technologies**

Julie Anne Overton

Director of Communications

[jao@bioaffinitytech.com](mailto:jao@bioaffinitytech.com)

Source: bioAffinity Technologies, Inc.